中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2013年
24期
6-7,8
,共3页
卵巢癌%培美曲塞%奈达铂
卵巢癌%培美麯塞%奈達鉑
란소암%배미곡새%내체박
Ovarian cancer%Pemetrexed%Nedaplatin
目的：观察培美曲塞联合奈达铂治疗复发晚期上皮性卵巢癌的疗效及毒副反应，主要研究终点为总反应率(ORR)，次要研究终点为无进展生存期(PFS)、总生存期(OS)及毒副反应。方法：收集34例复发晚期上皮性卵巢癌患者，所有患者均接受培美曲塞+奈达铂化疗：培美曲塞500 mg/m2+0.9%氯化钠溶液100 ml静脉滴注10 min，30 min后静脉滴注奈达铂80 mg/m2+0.9%氯化钠溶液500 ml，每21天重复一次。结果：所有患者均完成2~6程化疗，总反应率35.3％，铂类敏感组和铂类耐药组卵巢癌的反应率分别为40.0%和31.6%，两组比较差异无统计学意义(P>0.05)。铂类敏感组和铂类耐药组的PFS分别为6.7、5.8个月，OS分别为12.7、10.4个月。无药物相关性死亡事件发生，主要的3/4级毒副反应为中性粒细胞减少(11.7%)及血小板减少(5.9%)。结论：培美曲塞联合奈达铂治疗复发晚期卵巢癌疗效可，毒副反应可耐受。
目的：觀察培美麯塞聯閤奈達鉑治療複髮晚期上皮性卵巢癌的療效及毒副反應，主要研究終點為總反應率(ORR)，次要研究終點為無進展生存期(PFS)、總生存期(OS)及毒副反應。方法：收集34例複髮晚期上皮性卵巢癌患者，所有患者均接受培美麯塞+奈達鉑化療：培美麯塞500 mg/m2+0.9%氯化鈉溶液100 ml靜脈滴註10 min，30 min後靜脈滴註奈達鉑80 mg/m2+0.9%氯化鈉溶液500 ml，每21天重複一次。結果：所有患者均完成2~6程化療，總反應率35.3％，鉑類敏感組和鉑類耐藥組卵巢癌的反應率分彆為40.0%和31.6%，兩組比較差異無統計學意義(P>0.05)。鉑類敏感組和鉑類耐藥組的PFS分彆為6.7、5.8箇月，OS分彆為12.7、10.4箇月。無藥物相關性死亡事件髮生，主要的3/4級毒副反應為中性粒細胞減少(11.7%)及血小闆減少(5.9%)。結論：培美麯塞聯閤奈達鉑治療複髮晚期卵巢癌療效可，毒副反應可耐受。
목적：관찰배미곡새연합내체박치료복발만기상피성란소암적료효급독부반응，주요연구종점위총반응솔(ORR)，차요연구종점위무진전생존기(PFS)、총생존기(OS)급독부반응。방법：수집34례복발만기상피성란소암환자，소유환자균접수배미곡새+내체박화료：배미곡새500 mg/m2+0.9%록화납용액100 ml정맥적주10 min，30 min후정맥적주내체박80 mg/m2+0.9%록화납용액500 ml，매21천중복일차。결과：소유환자균완성2~6정화료，총반응솔35.3％，박류민감조화박류내약조란소암적반응솔분별위40.0%화31.6%，량조비교차이무통계학의의(P>0.05)。박류민감조화박류내약조적PFS분별위6.7、5.8개월，OS분별위12.7、10.4개월。무약물상관성사망사건발생，주요적3/4급독부반응위중성립세포감소(11.7%)급혈소판감소(5.9%)。결론：배미곡새연합내체박치료복발만기란소암료효가，독부반응가내수。
Objective:To investigate the efficacy and side effects of pemetrexed in combination with nedaplatin in the treatment of patients with recurrent and advanced epithelial ovarian cancer.The primary objective was to determine the overall response rate (ORR),secondary objectives included progression-free survival (PFS) and toxicity.Method:Collecting recurrent 34 cases with advanced epithelial ovarian cancer patients,all patients were accepted nida,pemetrexed plus cisplatin chemotherapy:pemetrexed 500 mg/m2+saline 100 ml intravenous drip 10 min,30 min after intravenous drip of nida platinum 500 ml,80 mg/m2+saline water once every 21 d repeat.Result:All the patients were completed 2-6 routine chemotherapy,35.3%of the total response rate,sensitive platinum and platinum resistance groups ovarian response rate were 40.0%and 31.6%respectively,the more similar between the two groups has no statistical significance (P>0.05). Sensitive platinum and platinum resistance groups of PFS were 6.7 and 5.8 months,OS 12.7 and 10.4 months respectively.No drug related deaths,the main grade 3/4 adverse reaction as neutropenia (11.7%) and thrombocytopenia (5.9%).Conclusion:Pemetrexed plus nedaplatin is effective in patients with recurrent and advanced epithelial ovarian cancer,including platinum-sensitive and platinum-resistant ovarian cancer.The adverse effects are tolerable.
